Trending News
News
News
MP Biomedicals LLC Initiates U.S. Clinical Trials for its MP Diagnostics™ HTLV Blot 2.4 Confirmatory Test
The assay is used in testing serum and plasma in the transfusion and transplantation community. The ongoing clinical data collection phase of the clinical trial is estimated to be completed within 4 – 6 weeks.
News
DuPont Affirms Strong Long-Term Growth Outlook
CEO Ellen Kullman and the company’s senior leaders detail the dynamic global growth strategy for continuing to deliver strong, sustainable results in 2012 and beyond.
News
Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc. announced that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie.
News
EU Commission Appoints First Ever Chief Scientific Adviser
The European commission has appointed Anne Glover as its first ever chief scientific adviser.
News
ProJect Pharmaceutics Introduces Predictive Formulation Analytics
The approach offers an innovative scientific approach for designing optimized protein formulations, and reduces the need for extensive stability testing.
News
Multistep Flow Synthesis of Vinyl Azides and their use in the Copper-Catalyzed Huisgen-type Cycloaddition under Inductive-Heating Conditions
In this article, researchers from Leibniz University Hannover report the multistep flow synthesis of vinyl azides and their application in the synthesis of vinyltriazoles.
News
R3Fusion Names Mark Beemer as President of Ethanol
As President of the company’s Ethanol Division Mark Beemer will be responsible for the development, deployment and execution of the ethanol water separation business for North America.
News
Celgene Announce Final Phase II Data Evaluating REVLIMID® and Rituximab
The study reported overall response rate of 66% in patients with relapsed or refractory chronic lymphocytic leukemia, with 12% of patients achieving complete response. After a median follow-up of 31 months, overall survival Was 75%.
News
Abbott and Reata Pharmaceuticals Announce Agreement for Next-Generation Antioxidant Inflammation Modulators
The companies announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata’s portfolio of second-generation oral antioxidant inflammation modulators (AIMs).
News
Marine Polysaccharides: A Source of Bioactive Molecules for Cell Therapy and Tissue Engineering
In this review article the authors describe how marine polysaccharides present a real potential for natural product drug discovery.
Advertisement